VNDA — Vanda Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1347178 ·
Last close
$3.81
Market Cap
$230.39M
52W High
$9.94
52W Low
$3.57
ADV30
1,152,709
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 50,529,000 | 46,969,000 | -63,809,000 | -62,513,000 | 412,467,000 | 55,882,000 | 192,282,000 |
| Mar 2026 | 51,718,000 | 48,559,000 | -50,224,000 | -48,567,000 | 433,525,000 | 54,034,000 | 152,760,000 |
| Dec 2025 | 57,216,000 | 53,383,000 | -40,353,000 | -141,187,000 | 488,948,000 | 84,851,000 | 161,762,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,331,000
Investing CF
$120,272,000
Financing CF
$-2,789,000
CapEx
$-10,674,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-505,846,000
Inventory
$1,678,000
Receivables
$59,692,000
ST Investments
$114,147,000
EBIT TTM
$-185,670,000
Pretax Income TTM
$-177,200,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$229,278,000
EBITDA
$-169,107,008
Free Cash Flow
$-85,866,872
Enterprise Value
$110,657,112
Total Cash
$140,494,000
Total Debt
$21,971,000
Shares Out
60,469,687
Trailing EPS
$-4.63
Book Value
$5.54
ROE
-82.5%
ROA
-22.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 216,105,000 | -151,168,000 | -220,474,000 | 488,948,000 | 161,762,000 | 327,186,000 | -109,442,000 |
| Dec 2024 | 198,772,000 | -40,660,000 | -18,900,000 | 656,204,000 | 117,658,000 | 538,546,000 | -15,757,000 |
| Dec 2023 | 192,640,000 | -13,952,000 | 2,509,000 | 648,440,000 | 103,530,000 | 544,910,000 | 12,801,000 |
| Dec 2022 | 254,382,000 | 6,329,000 | 6,275,000 | 634,247,000 | 107,049,000 | 527,198,000 | 31,984,000 |
TTM Snapshot
Revenues TTM
$215,721,000
NetIncome TTM
$-274,853,000
OpCashFlow TTM
—
Assets (Latest)
$412,467,000
Forward EPS
$0.20
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $3.75 · call volume: 113 · put volume: 20
Expected Move to 2026-12-18:
±$1.22
(32.53%) —
implied range
$2.53 –
$4.97
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc. | $229.72M | $7.97 | — |
| FTH | Faeth Therapeutics, Inc. | $233.63M | $9.04 | — |
| BIOA | BioAge Labs, Inc. | $234.35M | $5.10 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $235.60M | $2.11 | — |
| IMRX | Immuneering Corp | $224.08M | $3.46 | — |
News headlines (Yahoo Finance, 1h cache)
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
2026-11-11 14:00 · Yahoo
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
2026-11-03 21:30 · Yahoo
Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
2026-11-01 13:02 · Yahoo
Vanda (VNDA) Q3 2026 Earnings Call Transcript
2026-10-29 05:44 · Yahoo
Vanda Pharmaceuticals Q3 Earnings Call Highlights
2026-10-29 00:04 · Yahoo
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
2026-10-28 20:20 · Yahoo
Vanda: Q3 Earnings Snapshot
2026-10-28 20:11 · Yahoo
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-10-28 20:01 · Yahoo
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
2026-10-27 10:50 · Yahoo
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
2026-10-21 21:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.